[go: up one dir, main page]

ES2421929T3 - Nueva forma de administración de racecadotrilo - Google Patents

Nueva forma de administración de racecadotrilo

Info

Publication number
ES2421929T3
ES2421929T3 ES07731453T ES07731453T ES2421929T3 ES 2421929 T3 ES2421929 T3 ES 2421929T3 ES 07731453 T ES07731453 T ES 07731453T ES 07731453 T ES07731453 T ES 07731453T ES 2421929 T3 ES2421929 T3 ES 2421929T3
Authority
ES
Spain
Prior art keywords
racecadotril
administration
new form
core
comprisingcadcadotril
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES07731453T
Other languages
English (en)
Inventor
Jean-Charles Schwartz
Jeanne-Marie Lecomte
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioprojet SC
Original Assignee
Bioprojet SC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37552919&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2421929(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bioprojet SC filed Critical Bioprojet SC
Application granted granted Critical
Publication of ES2421929T3 publication Critical patent/ES2421929T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Comprimido de racecadotrilo constituido de un núcleo recubierto, dicho núcleo que comprenderacecadotrilo, de forma que el núcleo contiene, en peso: - del 20 al 50% de racecadotrilo; - del 20 al 40% de monohidrato de lactosa; - del 7 al 15% de carmelosa de calcio; - del 2 al 10% de hidroxipropilcelulosa; - del 5 al 10% de celulosa microcristalina; - del 2 al 10% de fécula pregelatinizada; - del 0,5 al 5% de estearato de magnesio.
ES07731453T 2006-05-15 2007-05-14 Nueva forma de administración de racecadotrilo Active ES2421929T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0604302A FR2900823B1 (fr) 2006-05-15 2006-05-15 Nouvelle forme d'administration du racecadotril.
PCT/FR2007/000814 WO2007132091A1 (fr) 2006-05-15 2007-05-14 Nouvelle forme d'administration du racecadotril

Publications (1)

Publication Number Publication Date
ES2421929T3 true ES2421929T3 (es) 2013-09-06

Family

ID=37552919

Family Applications (1)

Application Number Title Priority Date Filing Date
ES07731453T Active ES2421929T3 (es) 2006-05-15 2007-05-14 Nueva forma de administración de racecadotrilo

Country Status (28)

Country Link
US (1) US8318203B2 (es)
EP (1) EP2018158B1 (es)
KR (1) KR101432116B1 (es)
CN (2) CN101442990A (es)
AP (1) AP2627A (es)
AU (1) AU2007251471B2 (es)
BR (1) BRPI0710405B8 (es)
CA (1) CA2652023C (es)
CY (1) CY1114190T1 (es)
DK (1) DK2018158T3 (es)
EA (1) EA014707B1 (es)
EC (1) ECSP088889A (es)
ES (1) ES2421929T3 (es)
FR (1) FR2900823B1 (es)
HR (1) HRP20130624T1 (es)
IL (1) IL195270A (es)
MA (1) MA30466B1 (es)
MX (1) MX2008014554A (es)
NO (1) NO342977B1 (es)
NZ (1) NZ573424A (es)
PL (1) PL2018158T3 (es)
PT (1) PT2018158E (es)
RS (1) RS52912B (es)
SI (1) SI2018158T1 (es)
TN (1) TNSN08428A1 (es)
UA (1) UA98299C2 (es)
WO (1) WO2007132091A1 (es)
ZA (1) ZA200809721B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102018707A (zh) * 2010-11-29 2011-04-20 昆明邦宇制药有限公司 一种治疗腹泻的药物组合物及其制剂
CN102133186B (zh) * 2011-03-18 2012-08-01 海南美大制药有限公司 一种消旋卡多曲脂质体固体制剂
CN102166197B (zh) * 2011-04-25 2012-09-05 四川百利药业有限责任公司 消旋卡多曲颗粒及其生产工艺
JP2013180961A (ja) * 2012-02-29 2013-09-12 Astellas Pharma Inc Ｗｓ７２７７１３含有固形製剤
US9801819B2 (en) 2012-06-28 2017-10-31 Johnson & Johnson Consumer Inc. Racecadotril compositions
JP6282645B2 (ja) 2012-06-28 2018-02-21 ジヨンソン・アンド・ジヨンソン・コンシユーマー・インコーポレーテツドＪｏｈｎｓｏｎ ＆ Ｊｏｈｎｓｏｎ Ｃｏｎｓｕｍｅｒ Ｉｎｃ． ラセカドトリル脂質組成物
TR201801726T4 (tr) * 2012-12-26 2018-03-21 Ilko Ilac Sanayi Veticaret A S Rasekadotri̇l ve farmasöti̇k bi̇leşi̇mleri̇.
EP3086777A1 (en) * 2013-12-23 2016-11-02 Johnson & Johnson Consumer Inc. Racecadotril compositions
EP2918268A1 (en) 2014-03-10 2015-09-16 Galenicum Health S.L. Pharmaceutical compositions comprising an active agent
EP2949318A1 (en) 2014-05-26 2015-12-02 Galenicum Health S.L. Pharmaceutical compositions comprising racecadotril
MA40859A (fr) 2014-10-29 2017-09-05 Johnson & Johnson Consumer Inc Particules de cadotril
DK3256107T3 (da) 2015-02-09 2020-08-31 Rivopharm Sa Farmaceutisk formulering af racecadotril
CN106822907B (zh) * 2016-12-29 2021-02-09 山东达因海洋生物制药股份有限公司 一种含消旋卡多曲的双相释放制剂及其制备方法
RU2749949C2 (ru) * 2017-03-06 2021-06-21 Атена Фармасьютикс Сас Фармацевтическая композиция, содержащая рацекадотрил, и способ ее получения

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4401677A (en) * 1981-10-09 1983-08-30 E. R. Squibb & Sons, Inc. Enkephalinase inhibitors
ES2247163T3 (es) * 2000-06-23 2006-03-01 Bioprojet Formulacion en polvo seca que comprende racedotril.
GB0015490D0 (en) * 2000-06-23 2000-08-16 Smithkline Beecham Lab Novel formulations
GB0028575D0 (en) * 2000-11-23 2001-01-10 Elan Corp Plc Oral pharmaceutical compositions containing cyclodextrins
US20040253305A1 (en) * 2003-06-12 2004-12-16 Luner Paul E. Pharmaceutical compositions of atorvastatin
US20050027012A1 (en) * 2003-07-16 2005-02-03 Boehringer Ingelheim International Gmbh Tablets containing ambroxol
EP1563848A1 (en) * 2004-02-12 2005-08-17 Bioprojet New combinations of an anti-emetic agent and an enkephalinase inhibitor
DE602005024570D1 (de) * 2004-08-13 2010-12-16 Boehringer Ingelheim Pharma Tablettenformulierung mit verlängerter freisetzung mit pramipexol oder einem pharmazeutisch zulässigen salz davon, herstellungsverfahren und verwendung dafür
US20070254050A1 (en) * 2006-05-01 2007-11-01 Quart Barry D Method for treatment of diarrhea-predominant irritable bowel syndrome

Also Published As

Publication number Publication date
KR20090017593A (ko) 2009-02-18
US20090186084A1 (en) 2009-07-23
PL2018158T3 (pl) 2013-09-30
EP2018158B1 (fr) 2013-04-24
BRPI0710405A2 (pt) 2011-08-09
MA30466B1 (fr) 2009-06-01
NO20084826L (no) 2008-12-12
SI2018158T1 (sl) 2013-09-30
CN101442990A (zh) 2009-05-27
PT2018158E (pt) 2013-07-24
EA200802324A1 (ru) 2009-04-28
BRPI0710405B1 (pt) 2019-01-08
CA2652023C (fr) 2016-06-28
IL195270A (en) 2016-08-31
AU2007251471A1 (en) 2007-11-22
EA014707B1 (ru) 2011-02-28
CY1114190T1 (el) 2016-08-31
US8318203B2 (en) 2012-11-27
FR2900823B1 (fr) 2009-02-13
WO2007132091A1 (fr) 2007-11-22
ZA200809721B (en) 2009-06-24
HRP20130624T1 (en) 2013-08-31
FR2900823A1 (fr) 2007-11-16
CN103961328A (zh) 2014-08-06
UA98299C2 (ru) 2012-05-10
DK2018158T3 (da) 2013-07-22
BRPI0710405B8 (pt) 2021-05-25
KR101432116B1 (ko) 2014-08-21
AP2008004686A0 (en) 2008-12-31
RS52912B (sr) 2014-02-28
TNSN08428A1 (fr) 2010-04-14
NO342977B1 (no) 2018-09-17
IL195270A0 (en) 2009-08-03
ECSP088889A (es) 2009-01-30
AU2007251471B2 (en) 2012-03-15
AP2627A (en) 2013-03-26
MX2008014554A (es) 2008-11-27
CA2652023A1 (fr) 2007-11-22
EP2018158A1 (fr) 2009-01-28
NZ573424A (en) 2012-03-30

Similar Documents

Publication Publication Date Title
ES2421929T3 (es) Nueva forma de administración de racecadotrilo
CY1126116T1 (el) Φαρμακευτικες συνθεσεις αποτελουμενες απο νιλοτινιμπη
BRPI0719395C1 (pt) tablete revestido de filme
BRPI0719393B8 (pt) composição farmacêutica
BRPI0318456B8 (pt) tablete com liberação modificada
CL2012000887A1 (es) Mezcla fungicida sinergica que comprende fluorocitosina y otros compuestos fungicos; composicion fungicida que comprende dicha mezcla y un adyuvante agricolamente aceptable o portador.
PT2040755E (pt) Combinação de um inibidor de colinesterase e um composto com afinidade para o receptor 5-ht6
BRPI0906467C1 (pt) forma de dosagem farmacêutica com formato exterior modificado resistente à ruptura e com liberação controlada
AR122580A2 (es) Forma de dosificación de doxilamina y piridoxina y/o sus metabolitos o sales
HRP20120323T1 (en) Diarylhydantoin compounds
TW201000473A (en) Benzene or thiophene derivative and use thereof as VAP-1 inhibitor
ATE506340T1 (de) 12-aryl-prostaglandin-analoga
CL2009000914A1 (es) Compuestos derivados de 1-ciano-3-pirrolidinil-n-sustituidas-sulfonamidas, inhibidores de catepsina c; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una enfermedad pulmonar obstructiva cronica.
CL2007001752A1 (es) Compuesto 4-[5(2-amino-etansulfonil)-isoquinolin-7-il]-fenolo una sal farmaceuticamente aceptable o un hidrato o la sal del mismo;composicion farmaceutica que comprende a dicho compuesto,composicion farmaceutica liofilizada;y uso del compuesto como antineiplasico y/o antiviral.
JP2009537554A5 (es)
ECSP11011001A (es) Composición farmacéutica sólida
RU2008135718A (ru) Композиции клопидогреля бисульфата
CY1109865T1 (el) Συνθεσεις βαλσαρτανης
CL2008001990A1 (es) Compuestos derivados de amino-quinazolinas sustituidas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de alzheimer.
BRPI0607003A2 (pt) forma de dosagem com liberação sustentada e método para liberação sustentada de um composto de pirazina substituìda
JP2017537883A5 (es)
BR112012006433A2 (pt) composição de libertação sustentada de ranolazina
CL2012000350A1 (es) Combinacion farmaceutica que comprende un compuesto derivado de bifenilamida y un agente inhibidor de bcr-abl seleccionado de nilotinib; composicion farmaceutica; y uso de la combinacion para el tratamiento de leucemia positiva a bcr-abl.
JP2008031164A5 (es)
EA200801678A1 (ru) Применение производных триазина для производства лекарственного средства, обладающего заживляющим или ангиогенным эффектом